<i>atg7</i> -Based Autophagy Activation Reverses Doxorubicin-Induced Cardiotoxicity

  • Yong Wang
    Biochemistry and Molecular Biology (Y.W., X. Lu, Q.Q., P.Z., X.M., X. Lin, X.X.), Mayo Clinic, Rochester, MN.
  • Xiaoguang Lu
    Biochemistry and Molecular Biology (Y.W., X. Lu, Q.Q., P.Z., X.M., X. Lin, X.X.), Mayo Clinic, Rochester, MN.
  • Xiaoping Wang
    School of Traditional Chinese Medicine (Y.W., X.W., L.M., W.W.), Beijing University of Chinese Medicine, China.
  • Qi Qiu
    Biochemistry and Molecular Biology (Y.W., X. Lu, Q.Q., P.Z., X.M., X. Lin, X.X.), Mayo Clinic, Rochester, MN.
  • Ping Zhu
    Biochemistry and Molecular Biology (Y.W., X. Lu, Q.Q., P.Z., X.M., X. Lin, X.X.), Mayo Clinic, Rochester, MN.
  • Lin Ma
    School of Traditional Chinese Medicine (Y.W., X.W., L.M., W.W.), Beijing University of Chinese Medicine, China.
  • Xiao Ma
    Biochemistry and Molecular Biology (Y.W., X. Lu, Q.Q., P.Z., X.M., X. Lin, X.X.), Mayo Clinic, Rochester, MN.
  • Joerg Herrmann
    Cardiovascular Medicine (Y.W., X. Lu, Q.Q., P.Z., X.M., J.H., X. Lin, X.X.), Mayo Clinic, Rochester, MN.
  • Xueying Lin
    Biochemistry and Molecular Biology (Y.W., X. Lu, Q.Q., P.Z., X.M., X. Lin, X.X.), Mayo Clinic, Rochester, MN.
  • Wei Wang
    School of Traditional Chinese Medicine (Y.W., X.W., L.M., W.W.), Beijing University of Chinese Medicine, China.
  • Xiaolei Xu
    Biochemistry and Molecular Biology (Y.W., X. Lu, Q.Q., P.Z., X.M., X. Lin, X.X.), Mayo Clinic, Rochester, MN.

説明

<jats:sec> <jats:title>Rationale:</jats:title> <jats:p>Anthracycline-induced cardiotoxicity (AIC) is a major side effect that limits the use of anthracyclines as effective chemotherapeutics. No mechanism-based therapy is available when cardiac function deteriorates.</jats:p> </jats:sec> <jats:sec> <jats:title>Objective:</jats:title> <jats:p>We aim to elucidate the dynamic autophagic defects in AIC and to identify a mechanism-based therapy via both genetic and pharmacological studies.</jats:p> </jats:sec> <jats:sec> <jats:title>Method and Results:</jats:title> <jats:p> Through phenotyping an adult AIC zebrafish model, we detected a biphasic response in autophagy: activation in the early stage and suppression in the later phase that is characterized by a decline in cardiac function. We conducted conditional genetic studies with <jats:italic>atg7</jats:italic> , which encodes a rate-limiting autophagy core protein, and found that <jats:italic>atg7</jats:italic> overexpression leads to therapeutic effects in the late phase but deleterious effects in the early phase of adult AIC. We then assessed the therapeutic effects of 37 Food and Drug Administration–approved autophagy activators using an embryonic AIC zebrafish model and identified spironolactone, pravastatin, and minoxidil as top-ranking drugs. We demonstrated the therapeutic efficacy of these Food and Drug Administration–approved autophagy activators in the adult AIC model and confirmed that these drugs exert therapeutic effects in the late phase but not in the early AIC phase. Finally, we demonstrated that the time-dependent therapeutic effects are conserved in a mouse AIC model and that spironolactone and rapamycin activated autophagy in an Atg7-dependent fashion. </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Our findings suggest that atg7-based autophagy activation is an effective therapeutic avenue to reversing the decline in cardiac function in AIC, highlighting the time-dependent nature of autophagy-based therapy.</jats:p> </jats:sec>

収録刊行物

  • Circulation Research

    Circulation Research 129 (8), e166-, 2021-10

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ